Drug
E3810
E3810: highest development phase Phase 2/3, developed by Eisai. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Eisai
Trials
| Drug | Phase | Indication |
|---|---|---|
| E3810 NCT00770913 | Phase 2/3 | Refractory Reflux Esophagitis |
Latest
No recent events.
Follow E3810 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.